BNY Mellon Dynamic Value Fund

ANNUAL REPORT

August 31, 2021



Save time. Save paper. View your next shareholder report online as soon as it's available. Log into www.im.bnymellon.com and sign up for eCommunications. It's simple and only takes a few minutes. The views expressed in this report reflect those of the portfolio manager(s) only through the end of the period covered and do not necessarily represent the views of BNY Mellon Investment Adviser, Inc. or any other person in the BNY Mellon Investment Adviser, Inc. organization. Any such views are subject to change at any time based upon market or other conditions and BNY Mellon Investment Adviser, Inc. disclaims any responsibility to update such views. These views may not be relied on as investment advice and, because investment decisions for a fund in the BNY Mellon Family of Funds are based on numerous factors, may not be relied on as an indication of trading intent on behalf of any fund in the BNY Mellon Family of Funds. Not FDIC-Insured • Not Bank-Guaranteed • May Lose Value

Contents

THEFUND

Discussion of Fund Performance	2
Fund Performance	4
Understanding Your Fund's Expenses	7
Comparing Your Fund's Expenses	
With Those of Other Funds	7
Statement of Investments	8
Statement of Investments	
in Affiliated Issuers	12
Statement of Assets and Liabilities	13
Statement of Operations	14
Statement of Changes in Net Assets	15
Financial Highlights	17
Notes to Financial Statements	21
Report of Independent Registered	
Public Accounting Firm	31
Important Tax Information	32
Information About the Renewal and	
Approval of the Fund's Management Agreement and Approval of	
Sub-Investment Advisory Agreement	33
Liquidity Risk Management Program	40
Board Members Information	41
Officers of the Fund	43

FOR MORE INFORMATION

Back Cover

DISCUSSION OF FUND PERFORMANCE (Unaudited)

For the period from September 1, 2020 through August 31, 2021, as provided by Brian C. Ferguson, John C. Bailer and David S. Intoppa, Portfolio Managers

Market and Fund Performance Overview

For the 12-month period ended August 31, 2021, BNY Mellon Dynamic Value Fund's Class A shares produced a total return of 47.60%, Class C shares returned 46.48%, Class I shares returned 47.97% and Class Y shares returned 48.06%. The fund's benchmark, the Russell 1000® Value Index (the "Index"), produced a total return of 36.44% for the same period.

Stocks gained ground as government-mandated lockdowns were lifted, COVID-19 vaccines were approved, and the global economy continued to recover. The fund outperformed the Index, with value being added in all sectors.

The Fund's Investment Approach

The fund seeks capital appreciation. To pursue its goal, the fund normally invests at least 80% of its net assets, plus any borrowings for investment purposes, in stocks. The fund may invest up to 30% of its assets in foreign securities. We identify potential investments through extensive quantitative and fundamental research. We focus on individual stock selection (a "bottom-up" approach), emphasizing three key factors: value, sound business fundamentals and positive business momentum.

Stocks Rise Despite Concerns about Economic Recovery

During the reporting period, the global economy continued to show signs of recovery as government-mandated lockdowns were eased, and COVID-19 vaccines were approved. Growth-oriented stocks performed well early in the period, but with the approval of multiple COVID-19 vaccines late in November 2020, performance in the market broadened, and more cyclically oriented stocks began to perform better. This rotation continued through March 2021.

Returns were supported by interest rates, which remained low, as well as fiscal stimulus, which bolstered consumers, small businesses and the economy generally. Investors also began to factor the likelihood of infrastructure spending and other additional stimulus into their calculations.

Early in 2021, concerns about inflation arose, and interest rates began to rise. This took a toll on more growth-oriented stocks whose valuations had soared. In some emerging markets, central banks raised rates to combat rising prices, but generally central banks have been tolerant of pricing pressures.

With the emergence of the delta variant of COVID-19 midway through 2021, questions about whether the economic recovery would stall caused the market to pivot somewhat to more defensive and growth-oriented stocks. Nevertheless, markets were supported by strong corporate earnings worldwide, but especially in the U.S.

Mixed economic data weighed on markets later in the period, as did signals from the Federal Reserve, which suggested that policies might not be as supportive in the future. Nevertheless, the slowing of the recovery may benefit stocks worldwide as it may extend the recovery.

While valuations were low early in the period, they have largely recovered, helped in part by stronger corporate earnings. Earnings have been more favorable for cyclical companies hurt by the pandemic, but results from growth stocks have been favorable as well.

Performance Helped by Asset Allocation and Stock Selections

The fund's outperformance versus the Index was helped by stock selections in all sectors. Selections in the financial materials and information technology sectors were the primary contributors. In the financial sector, the fund's large overweight position was advantageous, as were holdings of Goldman

Sachs Group and Morgan Stanley, both of which climbed 105%, respectively. Both companies benefited from robust equity, fixed income and FX trading and Mergers and Acquisitions (M&A) activity. Capital One Financial, a consumer finance company, also performed well, benefiting from federal COVID-19 relief programs. *Ally Financial* also contributed positively. In the materials sector, the fund's overweight position was advantageous, as were shares of Freeport-McMoRan, a mining company, which rose 134% on strong demand for copper. In addition, shares of *Mosaic*, a fertilizer company, rose 61% as the economy continued to recover. In the information technology sector, an underweight position in information technology services was beneficial. Shares of Applied Materials, a semiconductor capital equipment company, and *NXP Semiconductors*, a chipmaker, also added to performance.

On a less positive note, performance in the real estate and consumer discretionary sectors was muted, though slightly positive. In real estate, the fund had very little exposure, selling *Weyerhaeuser*, a timber REIT, during the period. In the consumer discretionary sector, the fund had an underweight position, which was beneficial, but stock selections lagged.

Value Stocks Appear Relatively Attractive

We remain optimistic about the prospects for cyclical, income-oriented stocks. The extraordinary amount of fiscal stimulus that is in the works will benefit the economy and more cyclical, value-oriented stocks, which should benefit even if the economic recovery is slower and shallower than expected a few months ago. The economy continues to be supported by positive trends, and the Federal Reserve is unlikely to tighten monetary policy in the near term, while rising interest rates should benefit value-oriented securities. Strong earnings will help support valuations, which remain attractive.

September 15, 2021

- DUE TO RECENT MARKET VOLATILITY, CURRENT PERFORMANCE MAY BE DIFFERENT THAN THE FIGURES SHOWN. Investors should note that the fund's short-term performance is highly unusual, in part due to unusually favorable market conditions, and is unlikely to be repeated or consistently achieved in the future. Total return includes reinvestment of dividends and any capital gains paid and does not take into consideration the maximum initial sales charge in the case of Class A shares, or the applicable contingent deferred sales charges imposed on redemptions in the case of Class C shares. Had these charges been reflected, returns would have been lower. Past performance is no guarantee of future results. Share price and investment return fluctuate such that upon redemption, fund shares may be worth more or less than their original cost. The fund's returns reflect the absorption of certain fund expenses by BNY Mellon Investment Adviser, Inc. pursuant to an agreement in effect through December 31, 2021, at which time it may be extended, terminated or modified. Had these expenses not been absorbed, the fund's returns would have been lower.
- 2 Source: Lipper Inc. The Russell 1000% Value Index measures the performance of the large-cap value segment of the U.S. equity universe. It includes those Russell 1000 companies that are considered more value-oriented relative to the overall market, as defined by Russell's leading style methodology. The Russell 1000% Value Index is constructed to provide a comprehensive and unbiased barometer for the large-cap value segment. The index is completely reconstituted annually to ensure new and growing equities are included, and that the represented companies continue to reflect value characteristic annual value in the positive in the provision brief by the lighted with it divised to the few was cold during the reporting brief.


Please note: the position in any security highlighted with italicized typeface was sold during the reporting period.

Equities are subject generally to market, market sector, market liquidity, issuer and investment style risks, among other factors, to varying degrees, all of which are more fully described in the fund's prospectus.

The fund's performance will be influenced by political, social and economic factors affecting investments in foreign companies. Special risks associated with investments in foreign companies include exposure to currency fluctuations, less liquidity, less developed or less efficient trading markets, lack of comprehensive company information, political instability and differing auditing and legal standards. These risks are enhanced in emerging market countries. Please read the prospectus for further discussion of these risks.

Recent market risks include pandemic risks related to COVID-19. The effects of COVID-19 have contributed to increased volatility in global markets and will likely affect certain countries, companies, industries and market sectors more dramatically than others. To the extent the fund may overweight its investments in certain countries, companies, industries or market sectors, such positions will increase the fund's exposure to risk of loss from adverse developments affecting those countries, companies, industries or sectors.

FUND PERFORMANCE (Unaudited)




Comparison of change in value of a \$10,000 investment in Class A shares, Class C shares and Class I shares of BNY Mellon Dynamic Value Fund with a hypothetical investment of \$10,000 in the Russell 1000® Value Index (the "Index")

† Source: Lipper Inc.

Past performance is not predictive of future performance.

The above graph compares a hypothetical \$10,000 investment made in each of the Class A shares, Class C shares and Class I shares of BNY Mellon Dynamic Value Fund on 8/31/11 to a hypothetical investment of \$10,000 made in the Index on that date. All dividends and capital gain distributions are reinvested.

The fund's performance shown in the line graph above takes into account the maximum initial sales charge on Class A shares and all other applicable fees and expenses on Class A shares, Class C shares, and Class I shares. The Index measures the performance of the large-cap value segment of the U.S. equity universe. It includes those Russell 1000 companies that are considered more value-oriented relative to the overall market as defined by Russell's leading style methodology. The Russell 1000% V alue Index is constructed to provide a comprehensive and unbiased barometer for the large-cap value segment. The index is completely reconstituted annually to ensure new and growing equities are included and that the represented companies continue to reflect value characteristics. Unlike a mutual fund, the Index is not subject to charges, fees and other expenses. Investors cannot invest directly in any index. Further information relating to fund performance, including expense reimbursements, if applicable, is contained in the Financial Highlights section of the prospectus and elsewhere in this report.



Comparison of change in value of a \$1,000,000 investment in Class Y shares of BNY Mellon Dynamic Value Fund with a hypothetical investment of \$1,000,000 in the Russell 1000® Value Index (the "Index")

† Source: Lipper Inc.

Past performance is not predictive of future performance.

The above graph compares a hypothetical \$1,000,000 investment made in Class Y shares of BNY Mellon Dynamic Value Fund on 8/31/11 to a hypothetical investment of \$1,000,000 made in the Index on that date. All dividends and capital gain distributions are reinvested.

The fund's performance shown in the line graph above takes into account all applicable fees and expenses on Class Y shares. The Index measures the performance of the large-cap value segment of the U.S. equity universe. It includes those Russell 1000 companies that are considered more value-oriented relative to the overall market as defined by Russell's leading style methodology. The Russell 1000® V alue Index is constructed to provide a comprehensive and unbiased barometer for the large-cap value segment. The index is completely reconstituted annually to ensure new and growing equities are included and that the represented companies continue to reflect value characteristics. Unlike a mutual fund, the Index is not subject to charges, fees and other expenses. Investors cannot invest directly in any index. Further information relating to fund performance, including expense reimbursements, if applicable, is contained in the Financial Highlights section of the prospectus and elsewhere in this report.

The total return figures presented for Class Y shares of the fund reflect the performance of the fund's Class A shares for the period prior to 7/1/13 (the inception date for Class Y shares), not reflecting the applicable sales charges for Class A shares.

Average Annual Total Returns as of 8/31/2021							
	Inception						
	Date	1 Year	5 Years	10 Years			
Class A shares							
with maximum sales charge (5.75%)	9/29/95	39.11%	12.01%	12.92%			
without sales charge	9/29/95	47.60%	13.35%	13.59%			
Class C shares							
with applicable redemption charge †	5/31/01	45.48%	12.50%	12.74%			
without redemption	5/31/01	46.48%	12.50%	12.74%			
Class I shares	5/31/01	47.97%	13.64%	13.87%			
Class Y shares	7/1/13	48.06%	13.68%	13.86%††			
Russell 1000® Value Index		36.44%	11.68%	13.03%			

[†] The maximum contingent deferred sales charge for Class C shares is 1% for shares redeemed within one year of the date of purchase. †

The total return performance figures presented for Class Y shares of the fund reflect the performance of the fund's Class A shares for the period prior to 7/1/13 (the inception date for Class Y shares), not reflecting the applicable sales charges for Class A shares.

The performance data quoted represents past performance, which is no guarantee of future results. Share price and investment return fluctuate and an investor's shares may be worth more or less than original cost upon redemption. Current performance may be lower or higher than the performance quoted. Go to www.im.bnymellon.com for the fund's most recent month-end returns.

The fund's performance shown in the graphs and table does not reflect the deduction of taxes that a shareholder would pay on fund distributions or the redemption of fund shares. In addition to the performance of Class A shares shown with and without a maximum sales charge, the fund's performance shown in the table takes into account all other applicable fees and expenses on all classes.

UNDERSTANDING YOUR FUND'S EXPENSES (Unaudited)

As a mutual fund investor, you pay ongoing expenses, such as management fees and other expenses. Using the information below, you can estimate how these expenses affect your investment and compare them with the expenses of other funds. You also may pay one-time transaction expenses, including sales charges (loads) and redemption fees, which are not shown in this section and would have resulted in higher total expenses. For more information, see your fund's prospectus or talk to your financial adviser.

Review your fund's expenses

The table below shows the expenses you would have paid on a \$1,000 investment in BNY Mellon Dynamic Value Fund from March 1, 2021 to August 31, 2021. It also shows how much a \$1,000 investment would be worth at the close of the period, assuming actual returns and expenses.

Expenses and Value of a \$1,000 Investment Assume actual returns for the six months ended August 31, 2021						
	Class A	Class C	Class I	Class Y		
Expenses paid per \$1,000 [†]	\$5.06	\$9.12	\$3.70	\$3.43		
Ending value (after expenses)	\$1,157.30	\$1,153.00	\$1,158.60	\$1,159.20		

COMPARING YOUR FUND'S EXPENSES WITH THOSE OF OTHER FUNDS (Unaudited)

Using the SEC's method to compare expenses

The Securities and Exchange Commission ("SEC") has established guidelines to help investors assess fund expenses. Per these guidelines, the table below shows your fund's expenses based on a \$1,000 investment, assuming a hypothetical 5% annualized return. You can use this information to compare the ongoing expenses (but not transaction expenses or total cost) of investing in the fund with those of other funds. All mutual fund shareholder reports will provide this information to help you make this comparison. Please note that you cannot use this information to estimate your actual ending account balance and expenses paid during the period.

Expenses and Value of a \$1,000 Investment

Assuming a hypothetical 5% annualized return for the six months ended August 31, 2021

	Class A	Class C	Class I	Class Y
Expenses paid per \$1,000†	\$4.74	\$8.54	\$3.47	\$3.21
Ending value (after expenses)	\$1,020.52	\$1,016.74	\$1,021.78	\$1,022.03

[†] Expenses are equal to the fund's annualized expense ratio of .93% for Class A, 1.68% for Class C, .68% for Class I and .63% for Class Y, multiplied by the average account value over the period, multiplied by 184/365 (to reflect the one-half year period).

STATEMENT OF INVESTMENTS

August 31, 2021

Description	Shares	Value (\$)
Common Stocks - 98.8%		
Automobiles & Components5%		
General Motors	157,639 a	7,725,887
Banks - 3.9%		
JPMorgan Chase & Co.	189,223	30,266,219
U.S. Bancorp	148,286	8,510,134
Wells Fargo & Co.	621,680	28,410,776
		67,187,129
Capital Goods - 10.6%		
Carrier Global	374,082	21,547,123
Eaton	160,107	26,955,615
Howmet Aerospace	655,832	20,822,666
Hubbell	82,611	17,026,953
Ingersoll Rand	425,693 a	22,570,243
L3Harris Technologies	89,227	20,790,783
Northrop Grumman	55,714	20,486,038
Quanta Services	161,934	16,533,461
The Boeing Company	64,840 a	14,232,380
		180,965,262
Commercial & Professional Services5%		
CACI International, Cl. A	33,132 a	8,532,815
Consumer Services - 1.9%		
Booking Holdings	7,857 a	18,068,507
Expedia Group	95,895 a	13,856,828
		31,925,335
Diversified Financials - 15.3%		
Ameriprise Financial	133,053	36,311,494
Berkshire Hathaway, Cl. B	176,611 a	50,470,126
Capital One Financial	234,434	38,909,011
Equitable Holdings	284,597	8,825,353
LPL Financial Holdings	88,022	13,014,053
Morgan Stanley	295,439	30,852,695
The Charles Schwab	562,614	40,986,430
The Goldman Sachs Group	26,843	11,099,849
Voya Financial	468,595	30,449,303
		260,918,314
Energy - 7.2%		
Devon Energy	920,991	27,215,284
EQT	768,739 a	14,090,986
Exxon Mobil	599,448	32,681,905
Hess	293,343	20,167,331
Marathon Petroleum	483,567	28,661,016
		122,816,522

Common Stocks - 9.8-% (continued) Food, Beverage & Tobacco - 1.8% Philip Morris International 288,759 29,742,177 Health Care Equipment & Services - 15.4% 300,448° 17,636,622 Becton Dickinson & Co. 55,531 13,977,153 Centene 300,448° 18,922,215 CVS Health 207,216 17,901,390 Danaher 97,248 31,523,912 Dentsply Sirona 271,478 16,750,193 HCA Healthcare 52,449 13,268,548 Laboratory Corp. of America Holdings 58,258° 17,674,312 McKesson 84,523 17,254,525 Medronic 361,037 48,191,219 United Health Group 79,040 33,053,503 Zimmer Biomet Holdings 106,214 15,799,896 Easurant 256,418 43,619,266 Principal Financial Group 32,40 8,845,24 Willis Towers Watson 37,92 29,355,374 Alcoa 330,879° 14,681,01 CF Industries Holdings 491,981 22,345,777 <th>Description</th> <th>Shares</th> <th>Value (\$)</th>	Description	Shares	Value (\$)	
Philip Morris International 288,759 29,742,177 Health Care Equipment & Services - 15.4% 3 1,636,622 Becton Dickinson & Co. 55,531 13,977,153 Centene 300,448* 18,922,215 13,977,153 Centene 300,448* 18,922,215 17,901,390 Danaher 97,248 31,523,912 10,750,139 HCA Healthcare 52,449 13,268,548 16,750,193 HCA Healthcare 52,449 13,268,548 16,750,193 HCA Healthcare 361,037 48,191,219 361,037 48,191,219 McKesson 84,523 17,254,525 48,191,219 79,404 33,053,503 McHoronic 361,037 48,191,219 79,906 262,133,488 Insurance - 5.5% 36,022 48,191,219 79,906 262,133,488 Insurance - 5.5% 40,014 45,979,906 46,812,21 Assurant 77,342 22,186,326 22,186,326 Principal Financial Group 132,400 8,845,644 36,192,644	Common Stocks - 98.8% (continued)			
Plealth Care Equipment & Services - 15.4% 17.636,622 17.636,622 13.855 17.636,622 13.977,153 13.977,153 13.977,153 13.977,153 13.977,153 13.977,153 13.977,153 13.977,153 13.972,150 13.00,448° 18.922,215 17.91,390 13.00,448° 18.922,215 17.91,390 19.00,461 17.901,390 17.901,390 17.91,478 16.750,193 19.00,461 17.901,390 13.268,548 13.623,193 16.750,193 16.764,812 17.254,525 17.674,812 17.254,525 17.674,812 17.254,525 17.674,812 17.254,525 17.674,812 17.254,525 17.254,	Food, Beverage & Tobacco - 1.8%			
Alcon 213,855 17,636,622 Becton Dickinson & Co. 55,531 13,977,153 Centene 300,448* 18,922,215 CVS Health 207,216 17,901,390 Danaher 97,248 31,523,912 Dentsply Sirona 271,478 16,750,193 HCA Healthcare 52,449 13,268,548 Laboratory Corp. of America Holdings 58,258* 17,674,312 McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 UnitedHealth Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Ec2,133,488 18surance - 5.5% 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 Hactrals - 4.0% 41,681,101 26,148 43,619,266 Principal Financial Group 330,879* 14,681,101 22,448,344 McCr Industries Holdings 49,981 2	Philip Morris International	288,759	29,742,177	
Becton Dickinson & Co. 55,531 13,977,153 Centene 300,448* 18,922,121 CVS Health 207,216 17,901,390 Danaher 97,248 31,523,912 Dentsply Sirona 271,478 16,750,193 HCA Healthcare 52,449 13,266,543 Laboratory Corp. of America Holdings 58,258* 17,674,312 McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 United Health Group 79,404 33,053,508 Zimmer Biomet Holdings 106,214 15,979,896 Zimmer Biomet Holdings 106,214 15,979,896 Zimmer Biomet Holdings 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 33,400 8,845,644 Willis Towers Watson 87,692 19,355,378 Principal Financial Group 330,879* 14,681,101 Kel Loa 330,879* 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRa	Health Care Equipment & Services - 15.4%			
Centene 300,448 a 18,922,215 CVS Health 207,216 17,901,393 Dentsply Sirona 97,248 31,523,912 Dentsply Sirona 271,478 16,750,193 HCA Healthcare 52,449 13,268,548 Laboratory Corp. of America Holdings 58,258 a 17,674,312 McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 United Health Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Zo2,133,488 20,133,488 Insurance - 5.5% 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,666 Principal Financial Group 87,692 19,355,378 Willis Towers Watson 87,692 19,355,378 Alcoa 330,879 a 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials	Alcon	213,855		
CVS Health 207,216 17,901,390 Danaher 97,248 31,523,912 Dentsply Sirona 271,478 16,750,193 HCA Healthcare 52,449 13,268,548 Laboratory Corp. of America Holdings 58,258° 17,674,312 McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 UnitedHealth Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Z62,133,488 106,214 15,979,896 Z62,133,488 106,214 15,979,896 Z62,133,488 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 Willis Towers Watson 330,879° 14,681,101 Alcoa 330,879° 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport McMoRan 456,492 16,611,744 Martin Marietta Materials 37,93	Becton Dickinson & Co.	55,531	13,977,153	
Danaher 97,248 31,523,912 Dentsply Sirona 271,478 16,750,193 HCA Healthcare 52,449 13,268,548 Laboratory Corp. of America Holdings 58,258* 17,674,312 McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 UnitedHealth Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Zimmer Biomet Holdings 106,214 15,979,896 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 94,006,614 40,000 19,355,378 Holiustries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 67,932,828 Media & Entertainment - 5.3% 42,903 25,965,154 Alphabet, Cl. A 20,482* 63,805,810 Comcast, Cl. A	Centene	300,448 a	18,922,215	
Dentsply Sirona 271,478 16,750,193 HCA Healthcare 52,449 13,268,548 Laboratory Corp. of America Holdings 58,258° 17,674,312 McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 United Health Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Zo2,133,488 262,133,488 Insurance - 5.5% Aon, Cl. A 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 Materials - 4.0% 87,692 19,355,378 Alcoa 330,879° 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 Comcast, Cl. A 22,048° 63,805,810 ObbVie 42,703 25,965,154	CVS Health	207,216	17,901,390	
HCA Healthcare 52,449 13,268,548 Laboratory Corp. of America Holdings 58,258* 17,674,312 McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 UnitedHealth Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Zoz,133,488 Tangance - 5.5% Aon, Cl. A 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 Materials - 4.0% Tangantal Group 132,400 8,845,644 Willis Towers Watson 330,879* 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 22,048*	Danaher	97,248		
Laboratory Corp. of America Holdings 58,258 a 17,674,312 McKesson 84,523 a 17,254,525 Medtronic 361,037 a 81,91,219 United Health Group 79,404 a 35,053,503 Zimmer Biomet Holdings 106,214 b 15,979,896 Line Biomet Holdings 262,133,488 Insurance - 5.5% Aon, Cl. A 77,342 b 22,186,326 Assurant 256,418 b 36,19,266 Principal Financial Group 132,400 b 8,845,644 Willis Towers Watson 87,692 b 19,355,378 b 94,006,614 Materials - 4.0% 40,002 b 14,681,101 Alcoa 330,879 a 14,681,101 CF Industries Holdings 491,981 b 22,345,777 Freeport-McMoRan 456,492 b 16,611,744 Martin Marietta Materials 37,493 b 14,294,206 b 67,932,828 Media & Entertainment - 5.3% 22,048 a 63,805,810 b 67,932,828 Media & Entertainment - 5.3% 22,048 a 63,805,810 b 67,932,828 Media & Entertainment - 5.3% 22,048 a 63,805,810 b 67,932,828 Pharmaceuticals Biotechnology & Life Sciences - 7.4% 427,903 b 25,965,154 b 63,945,240 b 75,965,154	Dentsply Sirona	271,478	16,750,193	
McKesson 84,523 17,254,525 Medtronic 361,037 48,191,219 UnitedHealth Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Insurance - 5.5% Total State of Schafts Aon, Cl. A 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 313,400 8,845,644 Willis Towers Watson 330,879a 14,681,101 Materials - 4.0% 330,879a 14,681,101 CF Industries Holdings 491,981 22,345,701 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 Media & Entertainment - 5.3% 22,048a 63,805,810 Comcast, Cl. A 22,048a 63,805,810 <th< td=""><td>HCA Healthcare</td><td>52,449</td><td>13,268,548</td></th<>	HCA Healthcare	52,449	13,268,548	
Medtronic 361,037 48,191,219 UnitedHealth Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Insurance - 5.5% 262,133,488 Aon, Cl. A 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 49,006,614 400 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 Media & Entertainment - 5.3% 42,903 25,965,154 Alphabet, Cl. A 22,048* 63,805,810 Comcast, Cl. A 22,048* 63,805,810 Comcast, Cl. A 22,048* 69,91,555 Biogen 246,616 29,786,281 Biogen 20,482* 6,941,555 Elanco Animal Health 382,458* 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 41,528*	Laboratory Corp. of America Holdings	58,258 a	17,674,312	
UnitedHealth Group 79,404 33,053,503 Zimmer Biomet Holdings 106,214 15,979,896 Insurance - 5.5% 262,133,488 Insurant 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 Materials - 4.0% 400 330,879* 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 Media & Entertainment - 5.3% 42,048* 63,805,810 Alphabet, Cl. A 22,048* 63,805,810 Comcast, Cl. A 22,048* 63,805,810 Comcast, Cl. A 246,616 29,786,281 Biogen 246,616 29,786,281 Biogen 20,482* 6,941,555 Elanco Animal Health 382,458* 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 41,528* 8,923,537 <	McKesson	84,523	17,254,525	
Zimmer Biomet Holdings 106,214 15,979,896 Insurance - 5.5% 262,133,488 Aon, Cl. A 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 Materials - 4.0% 330,879 * 14,681,101 CF Industries Holdings 491,981 22,345,771 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% 22,048 * 63,805,810 Comcast, Cl. A 22,048 * 63,805,810 Comcast, Cl. A 22,048 * 63,805,810 Comcast, Cl. A 22,048 * 69,805,815 Biogen 246,616 29,786,281 Biogen 20,482 * 6,941,555 Elanco Animal Health 382,458 * 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 34,152 * 8,923,537 Viatris 95,183 8,707,527 <	Medtronic	361,037	48,191,219	
National Principal Financial Group 132,400 132,400 132,400 132,400 132,400 132,400 132,5378 14,681,101 132,400 132,400 132,400 132,5378 14,006,614	UnitedHealth Group	79,404	33,053,503	
Name	Zimmer Biomet Holdings	106,214	15,979,896	
Aon, Cl. A 77,342 22,186,326 Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 94,006,614 Materials - 4.0% Alcoa 330,879ª 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 Media & Entertainment - 5.3% Alphabet, Cl. A 22,048ª 63,805,810 Comcast, Cl. A 427,903 25,965,154 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482ª 6,941,555 Elanco Animal Health 382,458ª 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 41,528ª 8,923,537 Viatris 595,183 8,707,527 Lighe,681,231 <td cols<="" td=""><td></td><td></td><td>262,133,488</td></td>	<td></td> <td></td> <td>262,133,488</td>			262,133,488
Assurant 256,418 43,619,266 Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 94,006,614 94,006,614 Materials - 4.0% 330,879° 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 Media & Entertainment - 5.3% 4 67,932,828 Media & Entertainment - 5.3% 22,048° 63,805,810 Comcast, Cl. A 22,048° 63,805,810 Comcast, Cl. A 22,048° 63,805,810 Pharmaceuticals Biotechnology & Life Sciences - 7.4% 427,903 25,965,154 AbbVie 246,616 29,786,281 Biogen 20,482° 6,941,555 Elanco Animal Health 382,458° 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913° 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528° 8,923,537	Insurance - 5.5%			
Principal Financial Group 132,400 8,845,644 Willis Towers Watson 87,692 19,355,378 94,006,614 Materials - 4.0% 330,879° 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 67,932,828 Media & Entertainment - 5.3% 427,903 25,965,154 Alphabet, Cl. A 22,048° 63,805,810 Comcast, Cl. A 427,903 25,965,154 Pharmaceuticals Biotechnology & Life Sciences - 7.4% 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% 246,616 29,786,281 Biogen 20,482° 6,941,555 Elanco Animal Health 382,458° 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913° 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528° 8,923,537 Viatris 595,183 8,707,527 126,681,231 58<	Aon, Cl. A	77,342	22,186,326	
Willis Towers Watson 87,692 19,355,378 94,006,614 Materials - 4.0% 4003 330,879 a 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% 41,294,206 67,932,828 Media & Entertainment - 5.3% 422,048 a 63,805,810 Comcast, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 Pharmaceuticals Biotechnology & Life Sciences - 7.4% 427,903 25,965,154 AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Assurant	256,418	43,619,266	
94,006,614 Materials - 4.0% Alcoa 330,879 a 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% 22,048 a 63,805,810 Comcast, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% 426,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Principal Financial Group	132,400	8,845,644	
Materials - 4.0% Alcoa 330,879ª 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% Alphabet, Cl. A 22,048ª 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482ª 6,941,555 Elanco Animal Health 382,458ª 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913ª 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528ª 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Willis Towers Watson	87,692	19,355,378	
Alcoa 330,879 a 14,681,101 CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% Alphabet, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 Litenconductors & Semiconductor Equipment - 2.2%			94,006,614	
CF Industries Holdings 491,981 22,345,777 Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% Alphabet, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Materials - 4.0%			
Freeport-McMoRan 456,492 16,611,744 Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% Alphabet, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Alcoa	330,879 a	14,681,101	
Martin Marietta Materials 37,493 14,294,206 67,932,828 Media & Entertainment - 5.3% Alphabet, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	CF Industries Holdings	491,981	22,345,777	
67,932,828 Media & Entertainment - 5.3% Alphabet, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Freeport-McMoRan	456,492	16,611,744	
Media & Entertainment - 5.3% Alphabet, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Martin Marietta Materials	37,493	14,294,206	
Alphabet, Cl. A 22,048 a 63,805,810 Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%			67,932,828	
Comcast, Cl. A 427,903 25,965,154 89,770,964 Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Media & Entertainment - 5.3%			
Semiconductors & Semiconductor Equipment - 2.2% Sefection	Alphabet, Cl. A	22,048 a	63,805,810	
Pharmaceuticals Biotechnology & Life Sciences - 7.4% AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Comcast, Cl. A	427,903	25,965,154	
AbbVie 246,616 29,786,281 Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%			89,770,964	
Biogen 20,482 a 6,941,555 Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Pharmaceuticals Biotechnology & Life Sciences - 7.4%			
Elanco Animal Health 382,458 a 12,766,448 Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	AbbVie	246,616	29,786,281	
Eli Lilly & Co. 127,946 33,047,172 Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Biogen	20,482 a	6,941,555	
Horizon Therapeutics 84,913 a 9,178,246 Organon & Co. 511,374 17,330,465 United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Elanco Animal Health	382,458 a	12,766,448	
Organon & Co. 511,374 17,330,465 United Therapeutics 41,528a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Eli Lilly & Co.	127,946	33,047,172	
United Therapeutics 41,528 a 8,923,537 Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Horizon Therapeutics	84,913 a	9,178,246	
Viatris 595,183 8,707,527 126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	Organon & Co.	511,374	17,330,465	
126,681,231 Semiconductors & Semiconductor Equipment - 2.2%	United Therapeutics	41,528 a	8,923,537	
Semiconductors & Semiconductor Equipment - 2.2%	Viatris	595,183	8,707,527	
			126,681,231	
Applied Materials 126,365 17,075,702	Semiconductors & Semiconductor Equipment - 2.2%			
	Applied Materials	126,365	17,075,702	

STATEMENT OF INVESTMENTS (continued)

Description	Shares	Value (\$)
Common Stocks - 98.8% (continued)		
Semiconductors & Semiconductor Equipment - 2.2% (continued)		
Qualcomm	143,744	21,085,807
		38,161,509
Software & Services - 1.7%		
Dolby Laboratories, Cl. A	171,230	16,970,605
Fiserv	106,610 a	12,557,592
		29,528,197
Technology Hardware & Equipment - 6.2%		
Ciena	284,240 a	16,238,631
Cisco Systems	709,152	41,854,151
Corning	401,458	16,054,305
F5 Networks	79,766 a	16,237,965
Nokia, ADR	2,687,185 a	16,015,623
		106,400,675
Telecommunication Services8%		
Vodafone Group, ADR	798,617	13,632,392
Transportation - 1.7%		
FedEx	47,139	12,524,361
Union Pacific	74,424	16,138,100
		28,662,461
Utilities - 6.9%		
Clearway Energy, Cl. C	454,103	14,254,293
Exelon	953,830	46,756,747
NextEra Energy Partners	228,706	18,280,471
PPL	522,071	15,322,784
The AES	924,967	22,078,962
		116,693,257
Total Common Stocks (cost \$1,298,102,456)		1,683,417,057
Exchange-Traded Funds7%		
Registered Investment Companies7%		
iShares Russell 1000 Value ETF		
(cost \$12,357,485)	77,652	12,664,265

Description	1-Day Yield (%)	Shares	Value (\$)
Investment Companies2%			_
Registered Investment Companies2%			
Dreyfus Institutional Preferred Government Plus Money Market Fund, Institutional Shares			
(cost \$3,021,168)	0.06	3,021,168 b	3,021,168
Total Investments (cost \$1,313,481,109)		99.7%	1,699,102,490
Cash and Receivables (Net)		.3%	4,597,830
Net Assets		100.0%	1,703,700,320

ADR—American Depository Receipt

ETF—Exchange-Traded Fund

b Investment in affiliated issuer. The investment objective of this investment company is publicly available and can be found within the investment company's prospectus.

Portfolio Summary (Unaudited) †	Value (%)
Financials	24.8
Health Care	22.8
Industrials	12.8
Information Technology	10.2
Energy	7.2
Utilities	6.9
Communication Services	6.1
Materials	4.0
Consumer Discretionary	2.3
Consumer Staples	1.7
Investment Companies	.9
	99.7

[†] Based on net assets.

See notes to financial statements.

^a Non-income producing security.

STATEMENT OF INVESTMENTS IN AFFILIATED ISSUERS

Investment	Value	D 1 (4)	0.1 (#)	Value	Net	Dividends/
Companies		Purchases (\$)†	Sales (\$)	8/31/21 (\$)	Assets (%) Dist	ributions (\$)
Registered Inve	stment Comp	anies;				
Dreyfus						
Institutional						
Preferred						
Government						
Plus Money						
Market Fund,						
Institutional					_	
Shares		241,539,960	(238,518,792)	3,021,168	.2	2,180
Investment of C	ash Collatera	for Securities	Loaned:††			
Dreyfus						
Institutional						
Preferred						
Government						
Plus Money						
Market Fund,						
Institutional						
Shares	20,489,252	12,329,559	(32,818,811)	-	-	5,114†††
Dreyfus						
Institutional						
Preferred						
Government						
Plus Money						
Market Fund,		0.5.5.5	(05 545 404)			44.044
SL Shares	-	37,517,491	(37,517,491)	-	-	11,311†††
Total	20,489,252	291,387,010	(308,855,094)	3,021,168	.2	18,605

[†] Includes reinvested dividends/distributions.

^{##} Effective November 9, 2020, cash collateral for securities lending was transferred from Dreyfus Institutional Preferred Government Plus Money Market Fund, Institutional Shares to Dreyfus Institutional Preferred Government Plus Money Market Fund, SL Shares.

ttt Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

See notes to financial statements.

STATEMENT OF ASSETS AND LIABILITIES

August 31, 2021

	Cost	Value
Assets (\$):		
Investments in securities—See Statement of Investments	•	
Unaffiliated issuers	1,310,459,941	1,696,081,322
Affiliated issuers	3,021,168	3,021,168
Receivable for shares of Common Stock subscribed		3,719,374
Dividends receivable		2,688,507
Tax reclaim receivable—Note 1(b)		4,580
Prepaid expenses		53,231
		1,705,568,182
Liabilities (\$):		
Due to BNY Mellon Investment Adviser, Inc. and affiliates	—Note 3(c)	1,068,129
Payable for shares of Common Stock redeemed		575,424
Directors' fees and expenses payable		31,389
Other accrued expenses		192,920
		1,867,862
Net Assets (\$)		1,703,700,320
Composition of Net Assets (\$):		
Paid-in capital		1,064,112,068
Total distributable earnings (loss)		639,588,252
Net Assets (\$)		1,703,700,320

Net Asset Value Per Share	Class A	Class C	Class I	Class Y
Net Assets (\$)	881,741,093	7,011,299	476,539,631	338,408,297
Shares Outstanding	18,430,763	160,074	9,900,660	7,043,296
Net Asset Value Per Share (\$)	47.84	43.80	48.13	48.05

See notes to financial statements.

STATEMENT OF OPERATIONS

Year Ended August 31, 2021

Investment Income (\$):	
Income:	
Cash dividends (net of \$17,468 foreign taxes withheld at source):	
Unaffiliated issuers	26,467,373
Affiliated issuers	2,180
Income from securities lending—Note 1(c)	16,425
Total Income	26,485,978
Expenses:	
Management fee—Note 3(a)	8,745,314
Shareholder servicing costs—Note 3(c)	2,752,964
Professional fees	108,468
Directors' fees and expenses—Note 3(d)	94,378
Registration fees	73,241
Prospectus and shareholders' reports	61,566
Distribution fees—Note 3(b)	56,710
Loan commitment fees—Note 2	48,162
Custodian fees—Note 3(c)	30,930
Chief Compliance Officer fees—Note 3(c)	14,319
Interest expense—Note 2	1,492
Miscellaneous	51,492
Total Expenses	12,039,036
Less—reduction in expenses due to undertaking—Note 3(a)	(195,505)
Net Expenses	11,843,531
Investment Income—Net	14,642,447
Realized and Unrealized Gain (Loss) on Investments—Note 4 (\$):	
Net realized gain (loss) on investments and foreign currency transactions	288,628,473
Net change in unrealized appreciation (depreciation) on investments	248,196,725
Net Realized and Unrealized Gain (Loss) on Investments	536,825,198
Net Increase in Net Assets Resulting from Operations	551,467,645

See notes to financial statements.

STATEMENT OF CHANGES IN NET ASSETS

	Year Ended August 31,		
	2021		
Operations (\$):			
Investment income—net	14,642,447	20,060,398	
Net realized gain (loss) on investments	288,628,473	34,853,067	
Net change in unrealized appreciation			
(depreciation) on investments	248,196,725	(69,024,430)	
Net Increase (Decrease) in Net Assets			
Resulting from Operations	551,467,645	(14,110,965)	
Distributions (\$):		• • • •	
Distributions to shareholders:			
Class A	(19,041,891)	(25,395,218)	
Class C	(200,903)	(440,390)	
Class I	(10,550,171)	(16,654,035)	
Class Y	(7,275,644)	(8,883,603)	
Total Distributions	(37,068,609)	(51,373,246)	
Capital Stock Transactions (\$):		(, , ,	
Net proceeds from shares sold:			
Class A	34,136,670	23,294,794	
Class C	1,211,874	692,588	
Class I	92,552,281	98,524,788	
Class Y	99.963.364	41,059,106	
Distributions reinvested:	, ,	,,	
Class A	17,758,659	23,607,957	
Class C	181,276	334,420	
Class I	9,954,922	15,707,496	
Class Y	3,943,366	5,418,388	
Cost of shares redeemed:			
Class A	(94,142,782)	(96,480,564)	
Class C	(6,489,264)	(7,613,430)	
Class I	(110,915,218)	(196,500,842)	
Class Y	(64,179,793)	(74,590,633)	
Increase (Decrease) in Net Assets			
from Capital Stock Transactions	(16,024,645)	(166,545,932)	
Total Increase (Decrease) in Net Assets	498,374,391	(232,030,143)	
Net Assets (\$):			
Beginning of Period	1,205,325,929	1,437,356,072	
End of Period	1,703,700,320	1,205,325,929	

STATEMENT OF CHANGES IN NET ASSETS (continued)

	Year Ended August 31,		
	2021	2020	
Capital Share Transactions (Shares):			
Class Aa,b			
Shares sold	828,410	713,315	
Shares issued for distributions reinvested	474,450	651,629	
Shares redeemed	(2,361,065)	(2,915,370)	
Net Increase (Decrease) in Shares Outstanding	(1,058,205)	(1,550,426)	
Class Ca,b			
Shares sold	29,579	21,874	
Shares issued for distributions reinvested	5,261	9,995	
Shares redeemed	(181,276)	(247,262)	
Net Increase (Decrease) in Shares Outstanding	(146,436)	(215,393)	
Class I ^b			
Shares sold	2,186,641	3,063,057	
Shares issued for distributions reinvested	264,829	431,877	
Shares redeemed	(2,784,415)	(6,262,171)	
Net Increase (Decrease) in Shares Outstanding	(332,945)	(2,767,237)	
Class Y ^b			
Shares sold	2,380,906	1,400,714	
Shares issued for distributions reinvested	105,128	149,267	
Shares redeemed	(1,575,676)	(2,329,883)	
Net Increase (Decrease) in Shares Outstanding	910,358	(779,902)	

^a During the period ended August 31, 2021, 2,948 Class C shares representing \$108,123 were automatically converted to 2,710 Class A shares and during the period ended August 31, 2020, 3,386 Class C shares representing \$103,287 were automatically converted to 3,116 Class A shares.

See notes to financial statements.

During the period ended August 31, 2021, 33,586 Class Y shares representing \$1,451,558 were exchanged for 33,526 Class I shares, 2,071 Class Y shares representing \$78,874 were exchanged for 2,081 Class A shares, 173 Class C shares representing \$7,212 were exchanged for 158 Class I shares and 103 Class A shares representing \$4,595 were exchanged for 102 Class I shares. During the period ended August 31, 2020, 32,083 Class Y shares representing \$1,118,637 were exchanged for 32,028 Class I shares, 8,359 Class A shares representing \$258,938 were exchanged for 8,318 Class I shares, and 1,512 Class A shares representing \$54,664 were exchanged for 1,506 Class Y shares.

FINANCIAL HIGHLIGHTS

The following tables describe the performance for each share class for the fiscal periods indicated. All information (except portfolio turnover rate) reflects financial results for a single fund share. Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period, and redemption at net asset value on the last day of the period. Net asset value total return includes adjustments in accordance with accounting principles generally accepted in the United States of America and as such, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset value and returns for shareholder transactions. These figures have been derived from the fund's financial statements.

	Year Ended August 31,				
Class A Shares	2021	2020	2019	2018	2017
Per Share Data (\$):					
Net asset value, beginning of period	33.28	34.61	42.18	40.12	36.08
Investment Operations:					
Investment income—neta	.36	.47	.57	.49	.37
Net realized and unrealized gain					
(loss) on investments	15.20	(.56)	(2.67)	5.86	4.72
Total from Investment Operations	15.56	(.09)	(2.10)	6.35	5.09
Distributions:					
Dividends from investment					
income—net	(.22)	(.57)	(.63)	(.39)	(.49)
Dividends from net realized gain					
on investments	(.78)	(.67)	(4.84)	(3.90)	(.56)
Total Distributions	(1.00)	(1.24)	(5.47)	(4.29)	(1.05)
Net asset value, end of period	47.84	33.28	34.61	42.18	40.12
Total Return (%) ^b	47.60	(.55)	(4.40)	16.68	14.26
Ratios/Supplemental Data (%):					
Ratio of total expenses to					
average net assets	.95	.97	.96	.95	1.07
Ratio of net expenses to					
average net assets	.93	.93	.93	.93	.97
Ratio of net investment income to					
average net assets	.88	1.42	1.58	1.19	.95
Portfolio Turnover Rate	108.10	103.12	97.03	105.82	96.39
Net Assets, end of period (\$ x 1,000)	881,741	648,545	728,146	856,213	818,085

Based on average shares outstanding.

See notes to financial statements.

b Exclusive of sales charge.

FINANCIAL HIGHLIGHTS (continued)

			_		
	<u> </u>	Year Ended August 31,			
Class C Shares	2021	2020	2019	2018	2017
Per Share Data (\$):					
Net asset value, beginning of period	30.58	31.84	39.20	37.52	33.81
Investment Operations:					
Investment income—neta	.04	.20	.27	.17	.07
Net realized and unrealized gain					
(loss) on investments	13.96	(.53)	(2.48)	5.48	4.42
Total from Investment Operations	14.00	(.33)	(2.21)	5.65	4.49
Distributions:					
Dividends from investment					
income—net	-	(.26)	(.31)	(.07)	(.22)
Dividends from net realized gain					
on investments	(.78)	(.67)	(4.84)	(3.90)	(.56)
Total Distributions	(.78)	(.93)	(5.15)	(3.97)	(.78)
Net asset value, end of period	43.80	30.58	31.84	39.20	37.52
Total Return (%)b	46.48	(1.29)	(5.12)	15.86	13.39
Ratios/Supplemental Data (%):					
Ratio of total expenses to					
average net assets	1.73	1.73	1.71	1.71	1.84
Ratio of net expenses to					
average net assets	1.68	1.68	1.68	1.68	1.72
Ratio of net investment income to					
average net assets	.11	.66	.83	.45	.20
Portfolio Turnover Rate	108.10	103.12	97.03	105.82	96.39
Net Assets, end of period (\$ x 1,000)	7,011	9,372	16,615	29,482	42,611

Based on average shares outstanding. Exclusive of sales charge.

See notes to financial statements.

	Year Ended August 31,				
Class I Shares	2021	2020	2019	2018	2017
Per Share Data (\$):					
Net asset value, beginning of period	33.47	34.80	42.33	40.25	36.16
Investment Operations:					
Investment income—net ^a	.47	.56	.66	.59	.48
Net realized and unrealized gain					
(loss) on investments	15.28	(.56)	(2.68)	5.88	4.73
Total from Investment Operations	15.75	$(.00)^{b}$	(2.02)	6.47	5.21
Distributions:					
Dividends from investment					
income—net	(.31)	(.66)	(.67)	(.49)	(.56)
Dividends from net realized gain					
on investments	(.78)	(.67)	(4.84)	(3.90)	(.56)
Total Distributions	(1.09)	(1.33)	(5.51)	(4.39)	(1.12)
Net asset value, end of period	48.13	33.47	34.80	42.33	40.25
Total Return (%)	47.97	(.30)	(4.16)	16.99	14.58
Ratios/Supplemental Data (%):					
Ratio of total expenses to					
average net assets	.70	.71	.71	.72	.84
Ratio of net expenses to					
average net assets	.68	.68	.68	.68	.72
Ratio of net investment income to					
average net assets	1.13	1.67	1.83	1.44	1.21
Portfolio Turnover Rate	108.10	103.12	97.03	105.82	96.39
Net Assets, end of period (\$ x 1,000)	476,540	342,508	452,432	510,020	751,934

 ^a Based on average shares outstanding.
 ^b Amount represents less than \$.01 per share.
 See notes to financial statements.

FINANCIAL HIGHLIGHTS (continued)

	Year Ended August 31,				
Class Y Shares	2021				2017
Per Share Data (\$):	2021	2020	2017	2010	2017
Net asset value, beginning of period	33.41	34.74	42.35	40.25	36.16
Investment Operations:					
Investment income—neta	.49	.57	.67	.62	.48
Net realized and unrealized gain					
(loss) on investments	15.25	(.56)	(2.68)	5.87	4.73
Total from Investment Operations	15.74	.01	(2.01)	6.49	5.21
Distributions:					
Dividends from investment					
income—net	(.32)	(.67)	(.76)	(.49)	(.56)
Dividends from net realized gain					
on investments	(.78)	(.67)	(4.84)	(3.90)	(.56)
Total Distributions	(1.10)	(1.34)	(5.60)	(4.39)	(1.12)
Net asset value, end of period	48.05	33.41	34.74	42.35	40.25
Total Return (%)	48.06	(.27)	(4.13)	17.05	14.58
Ratios/Supplemental Data (%):					
Ratio of total expenses to					
average net assets	.64	.65	.65	.64	.75
Ratio of net expenses to					
average net assets	.64	.65	.65	.64	.71
Ratio of net investment income to	4.40	4.50	4.04	4 50	4.00
average net assets	1.18	1.70	1.84	1.50	1.22
Portfolio Turnover Rate	108.10	103.12	97.03	105.82	96.39
Net Assets, end of period (\$ x 1,000)	338,408	204,901	240,163	529,206	177,876

^a Based on average shares outstanding. See notes to financial statements.

NOTES TO FINANCIAL STATEMENTS

NOTE 1—Significant Accounting Policies:

BNY Mellon Dynamic Value Fund (the "fund") is a separate diversified series of BNY Mellon Advantage Funds, Inc. (the "Company"), which is registered under the Investment Company Act of 1940, as amended (the "Act"), as an open-end management investment company and operates as a series company currently offering nine series, including the fund. The fund's investment objective is to seek capital appreciation. BNY Mellon Investment Adviser, Inc. (the "Adviser"), a wholly-owned subsidiary of The Bank of New York Mellon Corporation ("BNY Mellon"), serves as the fund's investment adviser. Effective September 1, 2021 (the "Effective Date"), the Adviser has engaged its affiliate, Newton Investment Management North America, LLC ("Newton US") as the fund's subinvestment adviser pursuant to a sub-investment advisory agreement between the Adviser and Newton US. As the fund's sub-adviser, Newton US provides the day-to-day management of the fund's investments, subject to the Adviser's supervision and approval. The Adviser (and not the fund) pays Newton US for its sub-advisory services. As of the Effective Date, portfolio managers responsible for managing the fund's investments who were employees of Mellon Investments Corporation ("Mellon") in a dual employment arrangement with the Adviser, have become employees of Newton US and are no longer employees of Mellon.

BNY Mellon Securities Corporation (the "Distributor"), a wholly-owned subsidiary of the Adviser, is the distributor of the fund's shares. The fund is authorized to issue 800 million shares of \$.001 par value Common Stock. The fund currently has authorized four classes of shares: Class A (300 million shares authorized), Class C (100 million shares authorized), Class I (250 million shares authorized), and Class Y (150 million shares authorized). Class A and Class C shares are sold primarily to retail investors through financial intermediaries and bear Distribution and/or Shareholder Services Plan fees. Class A shares generally are subject to a sales charge imposed at the time of purchase. Class A shares bought without an initial sales charge as part of an investment of \$1 million or more may be charged a contingent deferred sales charge ("CDSC") of 1.00% if redeemed within one year. Class C shares are subject to a CDSC imposed on Class C shares redeemed within one year of purchase. Class C shares automatically convert to Class A shares eight years after the date of purchase, without the imposition of a sales charge. Class I shares are sold primarily to bank trust departments and other financial service providers (including The Bank of New York Mellon, a subsidiary of BNY Mellon and an affiliate of the Adviser, and its affiliates), acting on behalf of customers having a qualified trust or an investment account or relationship

at such institution, and bear no Distribution or Shareholder Services Plan fees. Class Y shares are sold at net asset value per share generally to institutional investors, and bear no Distribution or Shareholder Services Plan fees. Class I and Class Y shares are offered without a front-end sales charge or CDSC. Other differences between the classes include the services offered to and the expenses borne by each class, the allocation of certain transfer agency costs, and certain voting rights. Income, expenses (other than expenses attributable to a specific class), and realized and unrealized gains or losses on investments are allocated to each class of shares based on its relative net assets.

The Company accounts separately for the assets, liabilities and operations of each series. Expenses directly attributable to each series are charged to that series' operations; expenses which are applicable to all series are allocated among them on a pro rata basis.

The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") is the exclusive reference of authoritative U.S. generally accepted accounting principles ("GAAP") recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal laws are also sources of authoritative GAAP for SEC registrants. The fund is an investment company and applies the accounting and reporting guidance of the FASB ASC Topic 946 Financial Services-Investment Companies. The fund's financial statements are prepared in accordance with GAAP, which may require the use of management estimates and assumptions. Actual results could differ from those estimates.

The Company enters into contracts that contain a variety of indemnifications. The fund's maximum exposure under these arrangements is unknown. The fund does not anticipate recognizing any loss related to these arrangements.

(a) Portfolio valuation: The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price). GAAP establishes a fair value hierarchy that prioritizes the inputs of valuation techniques used to measure fair value. This hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

Additionally, GAAP provides guidance on determining whether the volume and activity in a market has decreased significantly and whether such a decrease in activity results in transactions that are not orderly.

GAAP requires enhanced disclosures around valuation inputs and techniques used during annual and interim periods.

Various inputs are used in determining the value of the fund's investments relating to fair value measurements. These inputs are summarized in the three broad levels listed below:

Level 1—unadjusted quoted prices in active markets for identical investments.

Level 2—other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.).

Level 3—significant unobservable inputs (including the fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy. Valuation techniques used to value the fund's investments are as follows:

Investments in equity securities are valued at the last sales price on the securities exchange or national securities market on which such securities are primarily traded. Securities listed on the National Market System for which market quotations are available are valued at the official closing price or, if there is no official closing price that day, at the last sales price. For open short positions, asked prices are used for valuation purposes. Bid price is used when no asked price is available. Registered investment companies that are not traded on an exchange are valued at their net asset value. All of the preceding securities are generally categorized within Level 1 of the fair value hierarchy.

Securities not listed on an exchange or the national securities market, or securities for which there were no transactions, are valued at the average of the most recent bid and asked prices. These securities are generally categorized within Level 2 of the fair value hierarchy.

Fair valuing of securities may be determined with the assistance of a pricing service using calculations based on indices of domestic securities and other appropriate indicators, such as prices of relevant American Depository Receipts and futures. Utilizing these techniques may result in transfers between Level 1 and Level 2 of the fair value hierarchy.

When market quotations or official closing prices are not readily available, or are determined not to accurately reflect fair value, such as when the

value of a security has been significantly affected by events after the close of the exchange or market on which the security is principally traded (for example, a foreign exchange or market), but before the fund calculates its net asset value, the fund may value these investments at fair value as determined in accordance with the procedures approved by the Company's Board of Directors (the "Board"). Certain factors may be considered when fair valuing investments such as: fundamental analytical data, the nature and duration of restrictions on disposition, an evaluation of the forces that influence the market in which the securities are purchased and sold, and public trading in similar securities of the issuer or comparable issuers. These securities are either categorized within Level 2 or 3 of the fair value hierarchy depending on the relevant inputs used.

For securities where observable inputs are limited, assumptions about market activity and risk are used and such securities are generally categorized within Level 3 of the fair value hierarchy.

The following is a summary of the inputs used as of August 31, 2021 in valuing the fund's investments:

		Level 2- Other	Level 3-	
	Level 1-	Significant	Significant	
	Unadjusted	Observable	Unobservable	
	Quoted Prices	Inputs	Inputs	Total
Assets (\$)				
Investments In Secu	ırities:†			
Equity Securities -				
Common Stocks	1,683,417,057	-	-	1,683,417,057
Exchange-Traded				
Funds	12,664,265	-	-	12,664,265
Investment				
Companies	3,021,168	-	-	3,021,168
	, ,	-	-	

[†] See Statement of Investments for additional detailed categorizations, if any.

(b) Foreign currency transactions: The fund does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in the market prices of securities held. Such fluctuations are included with the net realized and unrealized gain or loss on investments.

Net realized foreign exchange gains or losses arise from sales of foreign currencies, currency gains or losses realized on securities transactions between trade and settlement date, and the difference between the amounts of dividends, interest and foreign withholding taxes recorded on the fund's books and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains and losses arise from changes in the value of assets and liabilities other than investments

resulting from changes in exchange rates. Foreign currency gains and losses on foreign currency transactions are also included with net realized and unrealized gain or loss on investments.

Foreign taxes: The fund may be subject to foreign taxes (a portion of which may be reclaimable) on income, stock dividends, realized and unrealized capital gains on investments or certain foreign currency transactions. Foreign taxes are recorded in accordance with the applicable foreign tax regulations and rates that exist in the foreign jurisdictions in which the fund invests. These foreign taxes, if any, are paid by the fund and are reflected in the Statement of Operations, if applicable. Foreign taxes payable or deferred or those subject to reclaims as of August 31, 2021, if any, are disclosed in the fund's Statement of Assets and Liabilities.

(c) Securities transactions and investment income: Securities transactions are recorded on a trade date basis. Realized gains and losses from securities transactions are recorded on the identified cost basis. Dividend income is recognized on the ex-dividend date and interest income, including, where applicable, accretion of discount and amortization of premium on investments, is recognized on the accrual basis.

Pursuant to a securities lending agreement with The Bank of New York Mellon, the fund may lend securities to qualified institutions. It is the fund's policy that, at origination, all loans are secured by collateral of at least 102% of the value of U.S. securities loaned and 105% of the value of foreign securities loaned. Collateral equivalent to at least 100% of the market value of securities on loan is maintained at all times. Collateral is either in the form of cash, which can be invested in certain money market mutual funds managed by the Adviser, or U.S. Government and Agency securities. The fund is entitled to receive all dividends, interest and distributions on securities loaned, in addition to income earned as a result of the lending transaction. Should a borrower fail to return the securities in a timely manner, The Bank of New York Mellon is required to replace the securities for the benefit of the fund or credit the fund with the market value of the unreturned securities and is subrogated to the fund's rights against the borrower and the collateral. Additionally, the contractual maturity of security lending transactions are on an overnight and continuous basis. During the period ended August 31, 2021, The Bank of New York Mellon earned \$2,384 from the lending of the fund's portfolio securities, pursuant to the securities lending agreement.

(d) Affiliated issuers: Investments in other investment companies advised by the Adviser are considered "affiliated" under the Act.

- (e) Risk: Certain events particular to the industries in which the fund's investments conduct their operations, as well as general economic, political and public health conditions, may have a significant negative impact on the investee's operations and profitability. In addition, turbulence in financial markets and reduced liquidity in equity, credit and/or fixed income markets may negatively affect many issuers, which could adversely affect the fund. Global economies and financial markets are becoming increasingly interconnected, and conditions and events in one country, region or financial market may adversely impact issuers in a different country, region or financial market. These risks may be magnified if certain events or developments adversely interrupt the global supply chain; in these and other circumstances, such risks might affect companies worldwide. Recent examples include pandemic risks related to COVID-19 and aggressive measures taken world-wide in response by governments, including closing borders, restricting international and domestic travel, and the imposition of prolonged quarantines of large populations, and by businesses, including changes to operations and reducing staff. To the extent the fund may overweight its investments in certain countries, companies, industries or market sectors, such positions will increase the fund's exposure to risk of loss from adverse developments affecting those countries, companies, industries or sectors.
- (f) Dividends and distributions to shareholders: Dividends and distributions are recorded on the ex-dividend date. Dividends from investment income-net and dividends from net realized capital gains, if any, are normally declared and paid annually, but the fund may make distributions on a more frequent basis to comply with the distribution requirements of the Internal Revenue Code of 1986, as amended (the "Code"). To the extent that net realized capital gains can be offset by capital loss carryovers, it is the policy of the fund not to distribute such gains. Income and capital gain distributions are determined in accordance with income tax regulations, which may differ from GAAP.
- **(g)** Federal income taxes: It is the policy of the fund to continue to qualify as a regulated investment company, if such qualification is in the best interests of its shareholders, by complying with the applicable provisions of the Code, and to make distributions of taxable income and net realized capital gain sufficient to relieve it from substantially all federal income and excise taxes.

As of and during the period ended August 31, 2021, the fund did not have any liabilities for any uncertain tax positions. The fund recognizes interest and penalties, if any, related to uncertain tax positions as income tax

expense in the Statement of Operations. During the period ended August 31, 2021, the fund did not incur any interest or penalties.

Each tax year in the four-year period ended August 31, 2021 remains subject to examination by the Internal Revenue Service and state taxing authorities.

At August 31, 2021, the components of accumulated earnings on a tax basis were as follows: undistributed ordinary income \$94,056,294, undistributed capital gains \$177,960,874 and unrealized appreciation \$367,571,084.

The tax character of distributions paid to shareholders during the fiscal periods ended August 31, 2021 and August 31, 2020 were as follows: ordinary income \$9,311,148 and \$28,709,302, and long-term capital gains \$27,757,461 and \$22,663,944, respectively.

During the period ended August 31, 2021, as a result of permanent book to tax differences, primarily due to the tax treatment for treating a portion of the proceeds from redemptions as a distribution for tax purposes, the fund decreased total distributable earnings (loss) by \$14,322,592 and increased paid-in capital by the same amount. Net assets and net asset value per share were not affected by this reclassification.

NOTE 2—Bank Lines of Credit:

The fund participates with other long-term open-end funds managed by the Adviser in a \$823.5 million unsecured credit facility led by Citibank, N.A. (the "Citibank Credit Facility") and a \$300 million unsecured credit facility provided by The Bank of New York Mellon (the "BNYM Credit Facility"), each to be utilized primarily for temporary or emergency purposes, including the financing of redemptions (each, a "Facility"). The Citibank Credit Facility is available in two tranches: (i) Tranche A is in an amount equal to \$688.5 million and is available to all long-term openended funds, including the fund, and (ii) Tranche B is an amount equal to \$135 million and is available only to BNY Mellon Floating Rate Income Fund, a series of BNY Mellon Investment Funds IV, Inc. Prior to September 30, 2020, the Citibank Credit Facility was \$927 million with Tranche A available in an amount equal to \$747 million and Tranche B available in an amount equal to \$180 million. In connection therewith, the fund has agreed to pay its pro rata portion of commitment fees for Tranche A of the Citibank Credit Facility and the BNYM Credit Facility. Interest is charged to the fund based on rates determined pursuant to the terms of the respective Facility at the time of borrowing.

The average amount of borrowings outstanding under the Facilities during the period ended August 31, 2021 was approximately \$120,822 with a related weighted average annualized interest rate of 1.23%.

NOTE 3—Management Fee, Sub-Investment Advisory Fee and Other Transactions with Affiliates:

(a) Pursuant to a management agreement with the Adviser the management fee is computed at the annual rate of .60% of the value of the fund's average daily net assets and is payable monthly. The Adviser has contractually agreed, from September 1, 2020 through December 31, 2021, to waive receipt of its fees and/or assume the direct expenses of the fund, so that the direct expenses of none of the classes (excluding Rule 12b-1 Distribution Plan fees, Shareholder Services Plan fees, taxes, interest expense, brokerage commissions, commitment fees on borrowings and extraordinary expenses) exceed .68% of the value of the fund's average daily net assets. On or after December 31, 2021, the Adviser may terminate this expense limitation agreement at any time. The reduction in expenses, pursuant to the undertaking amounted to \$195,505 during the period ended August 31, 2021.

Effective as of the Effective Date, pursuant to a sub-investment advisory agreement between the Adviser and Newton US, the Adviser pays Newton US a monthly fee at an annual rate of .288% of the value of the fund's average daily net assets.

During the period ended August 31, 2021, the Distributor retained \$12,321 from commissions earned on sales of the fund's Class A shares and \$67 from CDSC fees on redemptions of the fund's Class C shares.

- **(b)** Under the Distribution Plan adopted pursuant to Rule 12b-1 under the Act, Class C shares pay the Distributor for distributing its shares at an annual rate of .75% of the value of its average daily net assets. The Distributor may pay one or more Service Agents in respect of advertising, marketing and other distribution services, and determines the amounts, if any, to be paid to Service Agents and the basis on which such payments are made. During the period ended August 31, 2021, Class C shares were charged \$56,710 pursuant to the Distribution Plan.
- **(c)** Under the Shareholder Services Plan, Class A and Class C shares pay the Distributor at an annual rate of .25% of the value of their average daily net assets for the provision of certain services. The services provided may include personal services relating to shareholder accounts, such as answering shareholder inquiries regarding the fund, and services related to the maintenance of shareholder accounts. The Distributor may make payments to Service Agents (securities dealers, financial institutions or

other industry professionals) with respect to these services. The Distributor determines the amounts to be paid to Service Agents. During the period ended August 31, 2021, Class A and Class C shares were charged \$1,939,546 and \$18,903, respectively, pursuant to the Shareholder Services Plan.

The fund has an arrangement with the transfer agent whereby the fund may receive earnings credits when positive cash balances are maintained, which are used to offset transfer agency fees. For financial reporting purposes, the fund includes net earnings credits, if any, as shareholder servicing costs in the Statement of Operations.

The fund has an arrangement with the custodian whereby the fund will receive interest income or be charged an overdraft fees when cash balances are maintained. For financial reporting purposes, the fund includes this interest income and overdraft fees, if any, as interest income in the Statement of Operations.

The fund compensates BNY Mellon Transfer, Inc., a wholly-owned subsidiary of the Adviser, under a transfer agency agreement for providing transfer agency and cash management services inclusive of earnings credits, if any, for the fund. The majority of transfer agency fees are comprised of amounts paid on a per account basis, while cash management fees are related to fund subscriptions and redemptions. During the period ended August 31, 2021, the fund was charged \$161,721 for transfer agency services, inclusive of earnings credit, if any. These fees are included in Shareholder servicing costs in the Statement of Operations.

The fund compensates The Bank of New York Mellon under a custody agreement for providing custodial services for the fund. These fees are determined based on net assets, geographic region and transaction activity. During the period ended August 31, 2021, the fund was charged \$30,930 pursuant to the custody agreement.

During the period ended August 31, 2021, the fund was charged \$14,319 for services performed by the Chief Compliance Officer and his staff. These fees are included in Chief Compliance Officer fees in the Statement of Operations.

The components of "Due to BNY Mellon Investment Adviser, Inc. and affiliates" in the Statement of Assets and Liabilities consist of: management fees of \$855,677, Distribution Plan fees of \$4,439, Shareholder Services Plan fees of \$186,754, custodian fees of \$10,800, Chief Compliance Officer fees of \$6,286 and transfer agency fees of \$26,357, which are offset against an expense reimbursement currently in effect in the amount of \$22,184.

(d) Each Board member also serves as a Board member of other funds in the BNY Mellon Family of Funds complex. Annual retainer fees and attendance fees are allocated to each fund based on net assets.

NOTE 4—Securities Transactions:

The aggregate amount of purchases and sales of investment securities, excluding short-term securities, during the period ended August 31, 2021, amounted to \$1,552,612,733 and \$1,597,312,503, respectively.

At August 31, 2021, the cost of investments for federal income tax purposes was \$1,331,531,378 accordingly, accumulated net unrealized appreciation on investments was \$367,571,112, consisting of \$393,371,965 gross unrealized appreciation and \$25,800,853 gross unrealized depreciation.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of BNY Mellon Dynamic Value Fund

Opinion on the Financial Statements

We have audited the accompanying statement of assets and liabilities of BNY Mellon Dynamic Value Fund (the "Fund") (one of the funds constituting BNY Mellon Advantage Funds, Inc.), including the statements of investments and investments in affiliated issuers, as of August 31, 2021, and the related statement of operations for the year then ended, the statements of changes in net assets for each of the two years in the period then ended, the financial highlights for each of the five years in the period then ended and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Fund (one of the funds constituting BNY Mellon Advantage Funds, Inc.) at August 31, 2021, the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period then ended and its financial highlights for each of the five years in the period then ended, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Fund's management. Our responsibility is to express an opinion on the Fund's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Fund is not required to have, nor were we engaged to perform, an audit of the Fund's internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of August 31, 2021, by correspondence with the custodian and others or by other appropriate auditing procedures where replies from others were not received. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Ernst + Young LLP

We have served as the auditor of one or more investment companies in the BNY Mellon Family of Funds since at least 1957, but we are unable to determine the specific year.

New York, New York October 22, 2021

IMPORTANT TAX INFORMATION (Unaudited)

For federal tax purposes, the fund hereby reports 99.96% of the ordinary dividends paid during the fiscal year ended August 31, 2021 as qualifying for the corporate dividends received deduction. Also certain dividends paid by the fund may be subject to a maximum tax rate of 15%, as provided for by the Jobs and Growth Tax Relief Reconciliation Act of 2003. Of the distributions paid during the fiscal year, \$9,307,997 represents the maximum amount that may be considered qualified dividend income. The fund also hereby reports \$.7814 per share as a long-term capital gain distribution paid on December 8, 2020. Shareholders will receive notification in early 2022 of the percentage applicable to the preparation of their 2021 income tax returns.

INFORMATION ABOUT THE RENEWAL AND APPROVAL OF THE FUND'S MANAGEMENT AGREEMENT AND APPROVAL OF SUB-INVESTMENT ADVISORY AGREEMENT (Unaudited)

At a meeting of the fund's Board of Directors held on March 8-9, 2021 (the "15(c) Meeting"), the Board considered the renewal of the fund's Management Agreement pursuant to which the Adviser provides the fund with investment advisory and administrative services (the "Agreement"). The Board members, none of whom are "interested persons" (as defined in the Investment Company Act of 1940, as amended (the "1940 Act")) of the fund (the "Independent Directors"), were assisted in their review by independent legal counsel and met with counsel in executive session separate from representatives of the Adviser. In considering the renewal of the Agreement, the Board considered several factors that it believed to be relevant, including those discussed below. The Board did not identify any one factor as dispositive, and each Board member may have attributed different weights to the factors considered.

Analysis of Nature, Extent, and Quality of Services Provided to the Fund. The Board considered information provided to it at the 15(c) Meeting and in previous presentations from representatives of the Adviser regarding the nature, extent, and quality of the services provided to funds in the BNY Mellon fund complex, including the fund. The Adviser provided the number of open accounts in the fund, the fund's asset size and the allocation of fund assets among distribution channels. The Adviser also had previously provided information regarding the diverse intermediary relationships and distribution channels of funds in the BNY Mellon fund complex (such as retail direct or intermediary, in which intermediaries typically are paid by the fund and/or the Adviser) and the Adviser's corresponding need for broad, deep, and diverse resources to be able to provide ongoing shareholder services to each intermediary or distribution channel, as applicable to the fund.

The Board also considered research support available to, and portfolio management capabilities of, the fund's portfolio management personnel and that the Adviser also provides oversight of day-to-day fund operations, including fund accounting and administration and assistance in meeting legal and regulatory requirements. The Board also considered the Adviser's extensive administrative, accounting and compliance infrastructures. The Board also considered portfolio management's brokerage policies and practices (including policies and practices regarding soft dollars) and the standards applied in seeking best execution.

Comparative Analysis of the Fund's Performance and Management Fee and Expense Ratio. The Board reviewed reports prepared by Broadridge Financial Solutions, Inc. ("Broadridge"), an independent provider of investment company data based on classifications provided by Thomson Reuters Lipper, which included information comparing (1) the performance of the fund's Class I shares with the performance of a group of institutional multi-cap value funds selected by Broadridge as comparable to the fund (the "Performance Group") and with a broader group of funds consisting of all retail and institutional multi-cap value funds (the "Performance Universe"), all for various periods ended December 31, 2020, and (2) the fund's actual and contractual management fees and total expenses with those of the same group of funds in the Performance Group (the "Expense Group") and with a broader group of all

INFORMATION ABOUT THE RENEWAL AND APPROVAL OF THE FUND'S MANAGEMENT AGREEMENT AND APPROVAL OF SUB-INVESTMENT ADVISORY AGREEMENT (Unaudited) (continued)

institutional multi-cap value funds, excluding outliers (the "Expense Universe"), the information for which was derived in part from fund financial statements available to Broadridge as of the date of its analysis. The Adviser previously had furnished the Board with a description of the methodology Broadridge used to select the Performance Group and Performance Universe and the Expense Group and Expense Universe.

Performance Comparisons. Representatives of the Adviser stated that the usefulness of performance comparisons may be affected by a number of factors, including different investment limitations and policies that may be applicable to the fund and comparison funds and the end date selected. The Board discussed with representatives of the Adviser the results of the comparisons and considered that the fund's total return performance was above the Performance Group and the Performance Universe medians for all periods, except the four-year period when it was one point below the Performance Group median. The Adviser also provided a comparison of the fund's calendar year total returns to the returns of the fund's benchmark index, and it was noted that the fund's returns were above the returns of the index in seven of the ten calendar years shown.

Management Fee and Expense Ratio Comparisons. The Board reviewed and considered the contractual management fee rate payable by the fund to the Adviser in light of the nature, extent and quality of the management services provided by the Adviser. In addition, the Board reviewed and considered the actual management fee rate paid by the fund over the fund's last fiscal year, which included reductions for a fee waiver arrangement in place that reduced the management fee paid to the Adviser. The Board also reviewed the range of actual and contractual management fees and total expenses as a percentage of average net assets of the Expense Group and Expense Universe funds and discussed the results of the comparisons.

The Board considered that the fund's contractual management fee was lower than the Expense Group median contractual management fee, the fund's actual management fee was lower than the Expense Group median and the Expense Universe median actual management fee and the fund's total expenses were lower than the Expense Group median and the Expense Universe median total expenses.

Representatives of the Adviser stated that the Adviser has contractually agreed, until December 31, 2021, to waive receipt of its fees and/or assume the direct expenses of the fund so that the direct expenses of none of its classes (excluding Rule 12b-1 fees, shareholder services fees, taxes, interest, brokerage commissions, commitment fees on borrowings and extraordinary expenses) exceed 0.68% of the fund's average daily net assets.

Representatives of the Adviser reviewed with the Board the management or investment advisory fees paid to the Adviser, or the primary employer of the fund's primary portfolio manager(s) that is affiliated with the Adviser, for advising any separate accounts and/or other types of client portfolios that are considered to have similar investment strategies and policies as the fund (the "Similar Clients"), and explained the nature of the Similar Clients. They discussed differences in fees paid and the relationship

of the fees paid in light of any differences in the services provided and other relevant factors. The Board considered the relevance of the fee information provided for the Similar Clients to evaluate the appropriateness of the fund's management fee. Representatives of the Adviser noted that there were no other funds advised or administered by the Adviser that are in the same Lipper category as the fund.

Analysis of Profitability and Economies of Scale. Representatives of the Adviser reviewed the expenses allocated and profit received by the Adviser and its affiliates and the resulting profitability percentage for managing the fund and the aggregate profitability percentage to the Adviser and its affiliates for managing the funds in the BNY Mellon fund complex, and the method used to determine the expenses and profit. The Board concluded that the profitability results were not excessive, given the services rendered and service levels provided by the Adviser and its affiliates. The Board also considered the expense limitation arrangement and its effect on the profitability of the Adviser and its affiliates. The Board also had been provided with information prepared by an independent consulting firm regarding the Adviser's approach to allocating costs to, and determining the profitability of, individual funds and the entire BNY Mellon fund complex. The consulting firm also had analyzed where any economies of scale might emerge in connection with the management of a fund.

The Board considered, on the advice of its counsel, the profitability analysis (1) as part of its evaluation of whether the fees under the Agreement, considered in relation to the mix of services provided by the Adviser, including the nature, extent and quality of such services, supported the renewal of the Agreement and (2) in light of the relevant circumstances for the fund and the extent to which economies of scale would be realized if the fund grows and whether fee levels reflect these economies of scale for the benefit of fund shareholders. Representatives of the Adviser stated that a discussion of economies of scale is predicated on a fund having achieved a substantial size with increasing assets and that, if a fund's assets had been stable or decreasing, the possibility that the Adviser may have realized any economies of scale would be less. Representatives of the Adviser also stated that, as a result of shared and allocated costs among funds in the BNY Mellon fund complex, the extent of economies of scale could depend substantially on the level of assets in the complex as a whole, so that increases and decreases in complex-wide assets can affect potential economies of scale in a manner that is disproportionate to, or even in the opposite direction from, changes in the fund's asset level. The Board also considered potential benefits to the Adviser from acting as investment adviser and took into consideration the soft dollar arrangements in effect for trading the fund's investments.

At the conclusion of these discussions, the Board agreed that it had been furnished with sufficient information to make an informed business decision with respect to the renewal of the Agreement. Based on the discussions and considerations as described above, the Board concluded and determined as follows.

• The Board concluded that the nature, extent and quality of the services provided by the Adviser are adequate and appropriate.

INFORMATION ABOUT THE RENEWAL AND APPROVAL OF THE FUND'S MANAGEMENT AGREEMENT AND APPROVAL OF SUB-INVESTMENT ADVISORY AGREEMENT (Unaudited) (continued)

- The Board was satisfied with the fund's performance.
- The Board concluded that the fee paid to the Adviser continued to be appropriate under the circumstances and in light of the factors and the totality of the services provided as discussed above.
- The Board determined that the economies of scale which may accrue to the Adviser and its affiliates in connection with the management of the fund had been adequately considered by the Adviser in connection with the fee rate charged to the fund pursuant to the Agreement and that, to the extent in the future it were determined that material economies of scale had not been shared with the fund, the Board would seek to have those economies of scale shared with the fund.

In evaluating the Agreement, the Board considered these conclusions and determinations and also relied on its previous knowledge, gained through meetings and other interactions with the Adviser and its affiliates, of the Adviser and the services provided to the fund by the Adviser. The Board also relied on information received on a routine and regular basis throughout the year relating to the operations of the fund and the investment management and other services provided under the Agreement, including information on the investment performance of the fund in comparison to similar mutual funds and benchmark performance indices; general market outlook as applicable to the fund; and compliance reports. In addition, the Board's consideration of the contractual fee arrangements for the fund had the benefit of a number of years of reviews of the Agreement for the fund, or substantially similar agreements for other BNY Mellon funds that the Board oversees, during which lengthy discussions took place between the Board and representatives of the Adviser. Certain aspects of the arrangements may receive greater scrutiny in some years than in others, and the Board's conclusions may be based, in part, on their consideration of the fund's arrangements, or substantially similar arrangements for other BNY Mellon funds that the Board oversees, in prior years. The Board determined to renew the Agreement.

At a meeting of the fund's Board of Directors held on May 11, 2021 (the "Meeting"), the Board discussed with representatives of the Adviser plans to realign Mellon Investments Corporation's ("Mellon") equities and multi-asset capabilities with Newton Investment Management North America, LLC ("Newton US") (the "Firm Realignment"), with such realignment scheduled to occur, subject to regulatory requirements, in the third quarter of 2021 (the "Effective Date"). The Adviser noted that, as a result of the Firm Realignment, the portfolio managers who are currently responsible for managing the investments of the fund as employees of Mellon in a dual employment arrangement with the Adviser, will become employees of Newton US as of the Effective Date. Consequently, the Adviser proposed to engage Newton US to serve as the fund's sub-investment adviser, pursuant to a sub-investment advisory agreement between the Adviser and Newton US (the "New Sub-Advisory Agreement"), to be effective on the Effective Date. In addition, the Adviser proposed amending the fund's current management agreement (the "Current Management Agreement") to reflect the

engagement of Newton US as sub-investment adviser to the fund (as proposed to be amended, the "Amended Management Agreement"), to be effective on the Effective Date.

At the Meeting, the Adviser recommended the approval of the New Sub-Advisory Agreement, pursuant to which Newton US would serve as sub-investment adviser to the fund, and the Amended Management Agreement. The recommendation for the approval of the New Sub-Advisory Agreement and the Amended Management Agreement was based on the following considerations, among others: (i) approval of the New Sub-Advisory Agreement and the Amended Management Agreement would permit the fund's current portfolio managers to continue to be responsible for the day-to-day management of the fund's portfolio after the Effective Date as employees of Newton US; (ii) there will be no material changes to the fund's investment objective, strategies or policies, no reduction in the nature or level of services provided to the fund, and no increases in the management fee payable by the fund as a result of the proposed changes to the investment advisory arrangements; and (iii) the Adviser (and not the fund) will pay Newton US for its sub-investment advisory services. The Board also considered the fact that the Adviser stated that it believes there are no material changes to the information the Board had previously considered at the 15(c) Meeting, at which the Board re-approved the Current Management Agreement for the ensuing year, other than the information about the Firm Realignment and Newton US.

At the Meeting, the Board members considered and approved the New Sub-Advisory Agreement and the Amended Management Agreement. In determining whether to approve the New Sub-Advisory Agreement and the Amended Management Agreement, the Board considered the materials prepared by the Adviser received in advance of the Meeting and other information presented at the Meeting, which included: (i) a form of the New Sub-Advisory Agreement and a form of the Amended Management Agreement; (ii) information regarding the Firm Realignment and how it is expected to enhance investment capabilities; (iii) information regarding Newton US; and (iv) an opinion of counsel that the proposed changes to the investment advisory arrangements would not result in an "assignment" of the Current Management Agreement under the 1940 Act and the Investment Advisers Act of 1940, as amended, and, therefore, do not require the approval of fund shareholders. The Board also considered the substance of discussions with representatives of the Adviser at the Meeting and the 15(c) Meeting.

Nature, Extent and Quality of Services to be Provided. In examining the nature, extent and quality of the services that were expected to be provided by Newton US to the fund under the New Sub-Advisory Agreement, the Board considered: (i) Newton US's organization, qualification and background, as well as the qualifications of its personnel; (ii) the expertise of the personnel providing portfolio management services, which would remain the same after the Effective Date; and (iii) the investment strategy for the fund, which would remain the same after the Effective Date. The Board also considered the review process undertaken by the Adviser and the Adviser's favorable assessment of the nature and quality of the sub-investment advisory services expected to be provided to the fund by Newton US after the Effective Date. Based on their consideration and

INFORMATION ABOUT THE RENEWAL AND APPROVAL OF THE FUND'S MANAGEMENT AGREEMENT AND APPROVAL OF SUB-INVESTMENT ADVISORY AGREEMENT (Unaudited) (continued)

review of the foregoing information, the Board concluded that the nature, extent and quality of the sub-investment advisory services to be provided by Newton US under the New Sub-Advisory Agreement, as well as Newton US's ability to render such services based on its resources and the experience of the investment team, which will include the fund's current portfolio managers, were adequate and appropriate for the fund in light of the fund's investment objective, and supported a decision to approve the New Sub-Advisory Agreement. The Board also considered, as it related to the Amended Management Agreement, that the nature, extent and quality of the services that are provided by the Adviser are expected to remain the same, including the Adviser's extensive administrative, accounting and compliance infrastructures, as well as the Adviser's supervisory activities over the fund's portfolio management personnel.

<u>Investment Performance</u>. The Board had considered the fund's investment performance and that of the investment team managing the fund's portfolio at the 15(c) Meeting (including comparative data provided by Broadridge Financial Solutions, Inc.). The Board considered the performance and that the same investment professionals would continue to manage the fund's assets after the Effective Date, as factors in evaluating the services to be provided by Newton US under the New Sub-Advisory Agreement after the Effective Date, and determined that these factors, when viewed together with the other factors considered by the Board, supported a decision to approve the New Sub-Advisory Agreement and the Amended Management Agreement.

Costs of Services to be Provided and Profitability. The Board considered the proposed fee payable under the New Sub-Advisory Agreement, noting that the proposed fee would be paid by the Adviser and, thus, would not impact the fees paid by the fund or the Adviser's profitability. The Board considered the fee payable to Newton US in relation to the fee paid to the Adviser by the fund and the respective services provided by Newton US and the Adviser. The Board recognized that, because Newton US's fee would be paid by the Adviser, and not the fund, an analysis of profitability was more appropriate in the context of the Board's consideration of the fund's Current Management Agreement, and that the Board had received and considered a profitability analysis of the Adviser and its affiliates, including Newton US, at the 15(c) Meeting. The Board concluded that the proposed fee payable to Newton US by the Adviser was appropriate and the Adviser's profitability was not excessive in light of the nature, extent and quality of the services to be provided to the fund by the Adviser under the Amended Management Agreement and Newton US under the New Sub-Advisory Agreement.

Economies of Scale to be Realized. The Board recognized that, because the fee payable to Newton US would be paid by the Adviser, and not the fund, an analysis of economies of scale was more appropriate in the context of the Board's consideration of the Current Management Agreement, which had been done at the 15(c) Meeting. At the 15(c) Meeting, the Board determined that the economies of scale which may accrue to the Adviser and its affiliates in connection with the management of the fund had been adequately considered by the Adviser in connection with the fee rate charged to the fund pursuant to the Current Management Agreement and that, to the extent in the

future it were determined that material economies of scale had not been shared with the fund, the Board would seek to have those economies of scale shared with the fund.

The Board also considered whether there were any ancillary benefits that would accrue to Newton US as a result of its relationship with the fund, and such ancillary benefits, if any, were determined to be reasonable.

In considering the materials and information described above, the Independent Directors received assistance from, and met separately with, their independent legal counsel, and were provided with a written description of their statutory responsibilities and the legal standards that are applicable to the approval of investment advisory and sub-investment advisory agreements.

After full consideration of the factors discussed above, with no single factor identified as being of paramount importance, the Board members, all of whom are Independent Directors, with the assistance of independent legal counsel, approved the New Sub-Advisory Agreement and Amended Management Agreement for the fund effective as of the Effective Date.

LIQUIDITY RISK MANAGEMENT PROGRAM (Unaudited)

Effective June 1, 2019, the fund adopted a liquidity risk management program (the "Liquidity Risk Management Program") pursuant to the requirements of Rule 22e-4 under the Investment Company Act of 1940, as amended. Rule 22e-4 requires registered open-end funds, including mutual funds and exchange-traded funds but not money market funds, to establish liquidity risk management programs in order to effectively manage fund liquidity and shareholder redemptions. The rule is designed to mitigate the risk that a fund could not meet redemption requests without significantly diluting the interests of remaining investors.

The rule requires the fund to assess, manage and review their liquidity risk at least annually considering applicable factors such as investment strategy and liquidity during normal and foreseeable stressed conditions, including whether the strategy is appropriate for an openend fund and whether the fund has a relatively concentrated portfolio or large positions in particular issuers. The fund must also assess its use of borrowings and derivatives, short-term and long-term cash flow projections in normal and stressed conditions, holdings of cash and cash equivalents, and borrowing arrangements and other funding sources.

The rule also requires the fund to classify its investments as highly liquid, moderately liquid, less liquid or illiquid based on the number of days the fund expects it would take to liquidate the investment, and to review these classifications at least monthly or more often under certain conditions. The periods range from three or fewer business days for a highly liquid investment to greater than seven calendar days for settlement of a less liquid investment. Illiquid investments are those a fund does not expect to be able to sell or dispose of within seven calendar days without significantly changing the market value. The fund is prohibited from acquiring an investment if, after the acquisition, its holdings of illiquid assets will exceed 15% of its net assets. In addition, if a fund permits redemptions in-kind, the rule requires the fund to establish redemption in-kind policies and procedures governing how and when it will engage in such redemptions.

Pursuant to the rule's requirements, the Liquidity Risk Management Program has been reviewed and approved by the Board. Furthermore, the Board has received a written report prepared by the Program's Administrator that addresses the operation of the Program, assesses its adequacy and effectiveness and describes any material changes made to the Program.

Assessment of Program

In the opinion of the Program Administrator, the Program approved by the Board continues to be adequate for the fund and the Program has been implemented effectively. The Program Administrator has monitored the fund's liquidity risk and the liquidity classification of the securities held by the fund and has determined that the Program is operating effectively.

During the period from January 1, 2020 to December 31, 2020, there were no material changes to the Program and no material liquidity events that impacted the fund. During the period, the fund held sufficient highly liquid assets to meet fund redemptions.

Under normal expected foreseeable fund redemption forecasts and foreseeable stressed fund redemption forecasts, the Program Administrator believes that the fund maintains sufficient highly liquid assets to meet expected fund redemptions.

BOARD MEMBERS INFORMATION (Unaudited) INDEPENDENT BOARD MEMBERS

Joseph S. DiMartino (77) Chairman of the Board (1995)

Principal Occupation During Past 5 Years:

 Director or Trustee of funds in the BNY Mellon Family of Funds and certain other entities (as described in the fund's Statement of Additional Information) (1995-Present)

Other Public Company Board Memberships During Past 5 Years:

 CBIZ, Inc., a public company providing professional business services, products and solutions, Director (1997-Present)

No. of Portfolios for which Board Member Serves: 97

Peggy C. Davis (78) Board Member (2006)

Principal Occupation During Past 5 Years:

• Shad Professor of Law, New York University School of Law (1983-Present)

No. of Portfolios for which Board Member Serves: 35

Gina D. France (63) Board Member (2019)

Principal Occupation During Past 5 Years:

 France Strategic Partners, a strategy and advisory firm serving corporate clients across the United States, Founder, President and Chief Executive Officer (2003-Present)

Other Public Company Board Memberships During Past 5 Years:

- Huntington Bancshares, a bank holding company headquartered in Columbus, Ohio, Director (2016-Present)
- Cedar Fair, L.P., a publicly-traded partnership that owns and operates amusement parks and hotels in the U.S. and Canada, *Director* (2011-Present)
- CBIZ, Inc., a public company providing professional business services, products and solutions, Director (2015-Present)
- FirstMerit Corporation, a diversified financial services company, *Director* (2004-2016)

No. of Portfolios for which Board Member Serves: 25

Joan Gulley (73) Board Member (2017)

Principal Occupation During Past 5 Years:

- Nantucket Atheneum, public library, Chair (2018-June 2021) and Director (2015-June 2021)
- Orchard Island Club, golf and beach club, Governor (2016-Present)

No. of Portfolios for which Board Member Serves: 43

BOARD MEMBERS INFORMATION (Unaudited) (continued) INDEPENDENT BOARD MEMBERS (continued)

Robin A. Melvin (57) Board Member (2012)

Principal Occupation During Past 5 Years:

- Westover School, a private girls' boarding school in Middlebury, Connecticut, Trustee (2019-Present)
- Mentor Illinois, a non-profit organization dedicated to increasing the quality of mentoring services in Illinois. Co-Chair (2014–2020); Board Member, Mentor Illinois (2013-2020)
- JDRF, a non-profit juvenile diabetes research foundation, Board Member (June 2021-Present)

Other Public Company Board Memberships During Past 5 Years:

 HPS Corporate Lending Fund, a closed-end management investment company regulated as a business development company, Trustee (August 2021-Present)

No o	f Port	folios	for	which	Board	Mem	her	Serves:	70	6
10. 0	1 1 0/1	lomos .	IUI	WIJUIJ	Doura	1110///	$\nu e r$	serves.	/ (U

Once elected all Board Members serve for an indefinite term, but achieve Emeritus status upon reaching age 80. The address of the Board Members and Officers is c/o BNY Mellon Investment Adviser, Inc. 240 Greenwich Street, New York, New York 10286. Additional information about the Board Members is available in the fund's Statement of Additional Information which can be obtained from the Adviser free of charge by calling this toll free number: 1-800-373-9387.

David P. Feldman, Emeritus Board Member Ehud Houminer, Emeritus Board Member Lynn Martin, Emeritus Board Member Dr. Martin Peretz, Emeritus Board Member Philip L. Toia, Emeritus Board Member

OFFICERS OF THE FUND (Unaudited)

DAVID DIPETRILLO, President since January 2021.

Vice President and Director of the Adviser since February 2021, Head of North America Product, BNY Mellon Investment Management since January 2018, Director of Product Strategy, BNY Mellon Investment Management from January 2016 to December 2017; He is an officer of 56 investment companies (comprised of 106 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 43 years old and has been an employee of BNY Mellon since 2005.

JAMES WINDELS, Treasurer since November 2001.

Vice President of the Adviser since September 2020, Director-BNY Mellon Fund Administration, and an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 62 years old and has been an employee of the Adviser since April 1985.

PETER M. SULLIVAN, Chief Legal Officer since July 2021 and Vice President and Assistant Secretary since March 2019.

Chief Legal Officer of the Adviser since July 2021, Associate General Counsel of BNY Mellon since July 2021; Senior Managing Counsel of BNY Mellon from December 2020 to July 2021; Managing Counsel of BNY Mellon from March 2009 to December 2020, and an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 53 years old and has been an employee of BNY Mellon since April 2004.

JAMES BITETTO, Vice President since August 2005 and Secretary since February 2018.

Senior Managing Counsel of BNY Mellon since December 2019; Managing Counsel of BNY Mellon from April 2014 to December 2019; Secretary of the Adviser, and an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 55 years old and has been an employee of the Adviser since December 1996.

DEIRDRE CUNNANE, Vice President and Assistant Secretary since March 2019.

Counsel of BNY Mellon since August 2018; Senior Regulatory Specialist at BNY Mellon Investment Management Services from February 2016 to August 2018. She is an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. She is 31 years old and has been an employee of the Adviser since August 2018.

SARAH S. KELLEHER, Vice President and Assistant Secretary since April 2014.

Managing Counsel of BNY Mellon since December 2017, Senior Counsel of BNY Mellon from March 2013 to December 2017. She is an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. She is 45 years old and has been an employee of the Adviser since March 2013.

JEFF PRUSNOFSKY, Vice President and Assistant Secretary since August 2005.

Senior Managing Counsel of BNY Mellon, and an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 56 years old and has been an employee of the Adviser since October 1990

AMANDA QUINN, Vice President and Assistant Secretary since March 2020.

Counsel of BNY Mellon since June 2019; Regulatory Administration Manager at BNY Mellon Investment Management Services from September 2018 to May 2019; Senior Regulatory Specialist at BNY Mellon Investment Management Services from April 2015 to August 2018. She is an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. She is 36 years old and has been an employee of the Adviser since June 2019.

NATALYA ZELENSKY, Vice President and Assistant Secretary since March 2017.

Chief Compliance Officer (since August 2021) and Vice President and Assistant Secretary (since February 2020) of BNY Mellon ETF Investment Adviser, LLC; Chief Compliance Officer (since August 2021) and Vice President (since February 2020) of BNY Mellon ETF Trust; Managing Counsel (December 2019 to August 2021) and Counsel (May 2016 to December 2019) of BNY Mellon; Assistant Secretary of the Adviser from April 2018 to August 2021. She is an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. She is 36 years old and has been an employee of BNY Mellon since May 2016.

GAVIN C. REILLY, Assistant Treasurer since December 2005.

Tax Manager-BNY Mellon Fund Administration, and an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 53 years old and has been an employee of the Adviser since April 1991.

ROBERT SALVIOLO, Assistant Treasurer since July 2007.

Senior Accounting Manager–BNY Mellon Fund Administration, and an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 54 years old and has been an employee of the Adviser since June 1989.

ROBERT SVAGNA, Assistant Treasurer since December 2002.

Senior Accounting Manager–BNY Mellon Fund Administration, and an officer of 57 investment companies (comprised of 128 portfolios) managed by the Adviser or an affiliate of the Adviser. He is 54 years old and has been an employee of the Adviser since November 1990.

JOSEPH W. CONNOLLY, Chief Compliance Officer since October 2004.

Chief Compliance Officer of the BNY Mellon Family of Funds and BNY Mellon Funds Trust since 2004, CCO of the Adviser from 2004 until June 2021 (56 investment companies, comprised of 119 portfolios). He is 64 years old and has served in various capacities with the Adviser since 1980, including manager of the firm's Fund Accounting Department from 1997 through October 2001.

CARIDAD M. CAROSELLA, Anti-Money Laundering Compliance Officer since January 2016.

Anti-Money Laundering Compliance Officer of the BNY Mellon Family of Funds and BNY Mellon Funds Trust. She is an officer of 50 investment companies (comprised of 121 portfolios) managed by the Adviser or an affiliate of the Adviser. She is 53 years old and has been an employee of the Distributor since 1997.

This page intentionally left blank.

For More Information

BNY Mellon Dynamic Value Fund

240 Greenwich Street New York, NY 10286

Adviser

BNY Mellon Investment Adviser, Inc. 240 Greenwich Street New York, NY 10286

Sub-Adviser

Newton Investment Management North America, LLC BNY Mellon Center 201 Washington Place Boston, MA 02108

Custodian

The Bank of New York Mellon 240 Greenwich Street New York, NY 10286

Transfer Agent & Dividend Disbursing Agent

BNY Mellon Transfer, Inc. 240 Greenwich Street New York, NY 10286

Distributor

BNY Mellon Securities Corporation 240 Greenwich Street New York, NY 10286

Ticker Symbols: Class A:DAGVX Class C:DCGVX Class I:DRGVX Class Y:DRGYX

Telephone Call your financial representative or 1-800-373-9387

Mail The BNY Mellon Family of Funds, 144 Glenn Curtiss Boulevard, Uniondale, NY 11556-0144

E-mail Send your request to info@bnymellon.com

Internet Information can be viewed online or downloaded at www.im.bnymellon.com

The fund files its complete schedule of portfolio holdings with the Securities and Exchange Commission ("SEC") for the first and third quarters of each fiscal year on Form N-PORT. The fund's Forms N-PORT are available on the SEC's website at www.sec.gov.

A description of the policies and procedures that the fund uses to determine how to vote proxies relating to portfolio securities and information regarding how the fund voted these proxies for the most recent 12-month period ended June 30 is available at www.im.bnymellon.com and on the SEC's website at www.sec.gov and without charge, upon request, by calling 1-800-373-9387.

